Abstracts Archive - Page 2455 of 2607 - ACR Meeting Abstracts

Abstract Number: 2225 • 2012 ACR/ARHP Annual Meeting
Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B)
Dominique L. Baeten¹, Stephan Bek², Jiawei Wei³, Arndt Brachat⁴, Joachim Sieper⁵, Paul Emery⁶, Jürgen Braun⁷, Desiree M. van der Heijde⁸, Iain B. McInnes⁹, Jacob M. van Laar¹⁰, R. Landewe¹¹, Paul Wordsworth¹², Jurgen Wollenhaupt¹³, Herbert Kellner¹⁴, Jacqueline E. Paramarta¹⁵, Arthur Bertolino¹⁶, Andrew Wright¹⁷ and Hueber Wolfgang², ¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Novartis Institutes for BioMedical Research, Basel, Switzerland, ³Integrated Information Sciences (IIS), Beijing Novartis Pharma Co. Ltd., Shanghai,, China, ⁴Novartis Pharma AG, Novartis Pharma AG, Basel, Switzerland, ⁵Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁶Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ¹⁰Newcastle University, Musculoskeletal Research Group, Newcastle, United Kingdom, ¹¹Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ¹²Nuffield Orthopaedic Centre, Oxford, United Kingdom, ¹³Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ¹⁴Centre for Inflammatory Joint Diseases, Munich, Germany, ¹⁵Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹⁶Translational Medicine- 3rd Floor, Novartis Institutes for BioMedical Research, Basel, Switzerland, ¹⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab has shown to be well tolerated and effective in active ankylosing spondylitis (AS) patients in a proof-of-concept trial1. Briefly, at Week (Wk) 6,…
Abstract Number: 2226 • 2012 ACR/ARHP Annual Meeting
Application of Classification Criteria for Psoriatic Arthritis to Patients of the Rotterdam Early Arthritis Cohort
Jos Van der Kaap¹, Johanna M.W. Hazes², M. Vis³, Ilya Tchetverikov⁴ and Jolanda J. Luime², ¹Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, VU University medical center, Amsterdam, Netherlands, ⁴Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) poses a diagnostic challenge due to lack of a clear case definition. This has led to varying reports on prevalence, which…
Abstract Number: 2227 • 2012 ACR/ARHP Annual Meeting
Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO
Bjorn Gudbjornsson¹ and Niels Steen Krogh², ¹Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ²ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: To explore differences in response to low dosage (2.3mg/kg) regimen of infliximab with possible escalating dosage in comparison to standard dosage of etanercept and…
Abstract Number: 2228 • 2012 ACR/ARHP Annual Meeting
The Caspar Classification Criteria and Response to TNF Blockade in Rheumatologists Practice: A Large Observational Cohort Study
Burkhard Moller¹, Almut Scherer², J. Dudler³, Bettina Weiss⁴, Nikhil Yawalkar⁵ and Peter M. Villiger⁶, ¹Rheumatology, Inselspital University Hospital, Bern, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Cantonal Hospital Fribourg, Fribourg, Switzerland, ⁴Division of Rheumatology, Balgrist University Hospital, Zurich, Switzerland, ⁵Dermatology, MD, Bern, Switzerland, ⁶Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland
The CASPAR classification criteria and response to TNF blockade in Rheumatologists' practice: A large observational cohort study Burkhard Möller, Almut Scherer, Jean Dudler, Bettina Weiss,…
Abstract Number: 2229 • 2012 ACR/ARHP Annual Meeting
Analysis of Clinical, CRP- and MRI- Responses to TNF-Blockade in Axial Spondyloarthritis Patients with Short Vs Long Symptom Duration
Anja Weiss¹, In-Ho Song², Hildrun Haibel², Joachim Listing³ and Joachim Sieper⁴, ¹German Rheumatism Research Centre, Berlin, Germany, ²Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany
Background/Purpose: To investigate the impact of disease duration on treatment response in patients with axial spondylarthritis (SPA) treated with etanercept (ETA) or adalimumab (ADA). Methods:…
Abstract Number: 2230 • 2012 ACR/ARHP Annual Meeting
The Early Clinical Response of TNF-Alpha Blockers Is a Predictor of Metrology Outcome in Ankylosing Spondylitis
Eon Jeong Nam¹, Jung Soo Eun¹, Na Ri Kim¹, Jong Wan Kang¹, Churl Hyun Im¹ and Young Mo Kang², ¹Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ²Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: TNF-a blocker is the only treatment that shows a significant effect on spinal inflammation and life quality of patients with ankylosing spondylitis (AS). However,…
Abstract Number: 2231 • 2012 ACR/ARHP Annual Meeting
Treatment of Psoriatic Arthritis with Tumour Necrosis Factor á Antagonists Successfully Maintains Work Capacity: 2 Year Results of a Prospective Cohort Study
Leonard C. Harty¹, Alex Franciosi², Naomi Pettysan², Paul Rushe² and Oliver M. FitzGerald¹, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Treatment resistant psoriatic arthritis (PsA) may render a patient unwell, disabled and incapable of work with previous reports suggesting that unemployment levels among PsA…
Abstract Number: 2232 • 2012 ACR/ARHP Annual Meeting
Performance of Berlin Criteria in Patients with EARLY Spondyloarthritis
Beatriz E. Joven¹, Milena Gobbo², Miguel A. Descalzo³, Eugenio De Miguel⁴ and Esperanza Group⁵, ¹Rheumatology, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, Madrid, Spain, ²Research Unit, Spanish Society of Rheumatology., Madrid, Spain, ³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁵Madrid
Background/Purpose: Berlin criteria are a diagnostic algorithm based on calculation of the likelihood ratio (LR) product of currently available diagnostic test for spondyloarthritis (SpA). However,…
Abstract Number: 2233 • 2012 ACR/ARHP Annual Meeting
Assessing the Clinical and Economic Burden of U.S. Veteran Ankylosing Spondylitis Patients
Lin Xie¹, Onur Baser², Ahong Huang³, Lu Li³, Elyse K. Fritschel³ and Li Wang⁴, ¹Director, Health Economics & Outcomes Research, STATinMED Research, Ann Arbor, MI, ²President/Adjunct Professor of Internal Medicine, STATinMED Research/The University of Michigan, Ann Arbor, MI, ³STATinMED Research, Dallas, TX, ⁴Director, Analytic Research, STATinMED Research, Dallas, TX
Background/Purpose: To examine the economic burden, demographic and clinical characteristics of ankylosing spondylitis (AS) in the U.S. veteran population. Methods: A retrospective database analysis…
Abstract Number: 2234 • 2012 ACR/ARHP Annual Meeting
US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab
Frank Zhang¹, Stan Li² and Jeffrey R. Curtis³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²Pricing and Market Access, Celgene Corporation, Warren, NJ, ³Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Etanercept (ETN) and Adalimumab (ADA) are commonly used biologic disease-modifying antirheumatic drugs (DMARDs) for psoriatic arthritis (PsA) patients (pts). However, little is known about…
Abstract Number: 2235 • 2012 ACR/ARHP Annual Meeting
How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters
Xenofon Baraliakos¹, Claudia Fritz², Joachim Listing³, Hildrun Haibel⁴, Joachim Sieper⁵ and Jürgen Braun⁶, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, ⁵Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, ⁶PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: Measures for disease activity (BASDAI) or response to therapy (ASAS partial remission (PR)) are widely used in the assessment of patients with ankylosing spondylitis…
Abstract Number: 2236 • 2012 ACR/ARHP Annual Meeting
Cross Cultural Validation of English and French Versions of a Disease Specific Patient Reported Outcome Measure for Lupus in Canada
Josiane Bourré-Tessier¹, Ann E. Clarke², Rachel A. Mikolaitis³, Mark Kosinski⁴, Sasha Bernatsky⁵, Joel A. Block³ and Meenakshi Jolly⁶, ¹Rheumatology, McGill University, Montréal, QC, Canada, ²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ³Section of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴QualityMetric Inc, Lincoln, RI, ⁵McGill University, Montreal, QC, Canada, ⁶Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: The LupusPRO, a disease targeted Patient Reported Outcome measure, was developed and validated in US patients with Systemic Lupus Erythematosus (SLE). We aimed to…
Abstract Number: 2237 • 2012 ACR/ARHP Annual Meeting
Application and Feasibility of Proposed Systemic Lupus Erythematosus Reproductive Health Care Quality Indicators At a Public Urban Rheumatology Clinic
Itziar Quinzanos¹, Angela Keniston², Joann Zell³, Jinoos Yazdany⁴, Alyssa Nash¹, Rebecca Fransen¹, Jennifer Stichman¹ and Joel M. Hirsh⁵, ¹Dept Medicine, Denver Health Med Ctr, Denver, CO, ²Department of Medicine, Denver Health and Hospital Authority, Denver, CO, ³Medicine, National Jewish Health, Denver, CO, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Medicine, Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO
Background/Purpose: Reproductive health quality indicators (QIs) for systemic lupus erythematosus (SLE) have recently been developed: anti-ssA, anti-ssB, and phospholipid antibody (aPL) screening prior to pregnancy;…
Abstract Number: 2238 • 2012 ACR/ARHP Annual Meeting
Alpha-Chlorofatty Acid Does Not Correlate with Baseline Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
Mary A. Mahieu¹, Camelia Guild², Carolyn J. Albert³, George Kondos⁴, James Carr⁵, Daniel Edmundowicz⁶, David A. Ford⁷ and Rosalind Ramsey-Goldman⁸, ¹Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Pediatrics and Center for Outcomes Research, Saint Louis University, Saint Louis, MO, ³Saint Louis University, Saint Louis, MO, ⁴University of Illinois at Chicago, Chicago, IL, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Temple University School of Medicine, Philadelphia, PA, ⁷Department of Biochemistry and Molecular Biology, Saint Louis University, Saint Louis, MO, ⁸Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Serum alpha-chlorofatty acid (α-ClFA) directly reflects in vivo myeloperoxidase activity, an important regulator of atherogenesis. The objective of our study was to investigate whether α-ClFA…
Abstract Number: 2239 • 2012 ACR/ARHP Annual Meeting
Characterization of Pure Membranous Lupus Nephritis: A Cohort of 150 Patients
Lucía Silva¹, Teresa Oton¹, Anca Askanase², Patricia Carreira³, Francisco Javier López-Longo⁴, Anne Riveros⁵, Íñigo Rúa-Figueroa⁶, Javier Narvaez⁷, Esther Ruiz-Lucea⁸, Mariano Andres⁹, Enrique Calvo¹⁰, Francisco Toyos¹¹, Juan J. Alegre¹², Eva Tomero¹³, Carlos Montilla¹⁴, Antonio Zea¹⁵, Esther Uriarte-Isacelaya¹⁶, Jaime Calvo-Alen¹⁷, Carlos Marras¹⁸, Víctor M. Martínez-Taboada¹⁹, María Ángeles Belmonte²⁰, Jose Rosas²¹, Enrique Raya²², Gema Bonilla²³ and Mercedes Freire²⁴, ¹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, ²NYU School of Medicine, New York, NY, ³Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañón, Department of Rheumatology, Madrid, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁶Rheumatology, Hospital Universitario Dr Negrín. Las Palmas, Las Palmas de Gran Canaria, Spain, ⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Rheumatology, Hospital de Basurto, Bilbao, Spain, ⁹Seccion Reumatologia, Hospital General Universitario de Alicante, Alicante, Spain, ¹⁰Rheumatology, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Spain, ¹¹Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹²Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ¹³Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁴Unit Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, ¹⁵Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁶Rheumatology, Hospital Universitario de Donostia, Donosti, Spain, ¹⁷Rheumatology, Hospital Sierrallana. Torrelavega, Torrelavega, Spain, ¹⁸Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ²⁰Rheumatology, Hospital Universitario Carlos Haya, Málaga, Spain, ²¹Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ²²Rheumatology, University Hospital San Cecilio, Granada, Spain, ²³Rheumatology, Hospital La Paz, Madrid, Spain, ²⁴Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain
Background/Purpose : Over 50% of patients with SLE develop renal involvement but only 20% of these are found to have pure membranous lupus neprhitis (MLN)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].